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CD8CD205 Splenic Dendritic Cells Are Specialized to
Induce Foxp3 Regulatory T Cells1
Sayuri Yamazaki,2,3* Diana Dudziak,2†‡ Gordon F. Heidkamp,†‡ Christopher Fiorese,*
Anthony J. Bonito,* Kayo Inaba,§¶ Michel C. Nussenzweig,† and Ralph M. Steinman*
Foxp3CD25CD4 regulatory T cells (Treg) mediate immunological self-tolerance and suppress immune responses. A subset of
dendritic cells (DCs) in the intestine is specialized to induce Treg in a TGF-- and retinoic acid-dependent manner to allow for oral
tolerance. In this study we compare two major DC subsets from mouse spleen. We find that CD8 DEC-205/CD205 DCs, but not the
major fraction of CD8 DC inhibitory receptor-2 (DCIR2) DCs, induce functional Foxp3 Treg from Foxp3 precursors in the
presence of low doses of Ag but without added TGF-. CD8CD205 DCs preferentially express TGF-, and the induction of Treg by
these DCs in vitro is blocked by neutralizing Ab to TGF-. In contrast, CD8DCIR2 DCs better induce Foxp3 Treg when exogenous
TGF- is supplied. In vivo, CD8CD205 DCs likewise preferentially induce Treg from adoptively transferred, Ag-specific DO11.10
RAG/ Foxp3CD4 T cells, whereas the CD8DCIR2 DCs better stimulate natural Foxp3 Treg. These results indicate that a
subset of DCs in spleen, a systemic lymphoid organ, is specialized to differentiate peripheral Foxp3 Treg, in part through the endog-
enous formation of TGF-. Targeting of Ag to these DCs might be useful for inducing Ag-specific Foxp3 Treg for treatment of
autoimmune diseases, transplant rejection, and allergy. The Journal of Immunology, 2008, 181: 6923–6933.
N aturally occurring Foxp3
CD25CD4 regulatory T
cells (Treg),4 which express the Foxp3 transcription fac-
tor and high affinity IL-2 receptor (CD25), derive from
the thymus and sustain self-tolerance (1). Foxp3 Treg can also be
differentiated or induced from conventional Foxp3CD25CD4
T cells in the periphery with some stimuli such as TGF- supple-
mentation (2–6). Natural and induced Foxp3 Treg suppress au-
toimmunity as well as allergy, graft rejection, and immune re-
sponses to microbes and tumors (1, 5, 7–10). It is important to
understand the generation of Ag-specific Foxp3 Treg to be able
to suppress immunity in an Ag-specific manner and avoid global
immune suppression by polyclonal Treg.
T cell responses are controlled by dendritic cells (DCs). DCs are
APCs specialized to capture and process Ags for presentation on
MHC products and then to control the subsequent differentiation of T
cells (11–13). Two such specializations are the expression of numer-
ous receptors that mediate Ag uptake and processing (14, 15) and
localization to the T cell-rich areas of peripheral lymphoid organs (16,
17). DCs initiate T cell immunity but can also induce tolerance, as is
desirable in the case of harmless self and environmental Ags (18–20).
Tolerance can develop by different pathways such as deletion (21, 22),
induction of CD5 (23), or both induction and expansion of Treg (5,
24–31). We have recently shown that relative to bulk spleen cells,
DCs are much more effective inducers of functional Foxp3 Treg
from Foxp3 peripheral CD4 T cells (9).
Classical DCs in mouse spleen are comprised of two major sub-
sets that express distinct markers and functions (12, 32, 33). One
subset is CD8 and DEC-205/CD205, and the second is
CD8CD205 and DC inhibitory receptor-2 (DCIR2); the latter
is recognized by the 33D1 mAb (32, 34, 35). Splenic DC subsets
can have different functions in T cell differentiation, e.g., CD8
CD205 DCs can induce IFN--producing Th1 T cells whereas
CD8DCIR2 DCs induce Th2 responses (36–39). DC subsets,
marked by the presence or absence of the CD103 integrin, are also
evident in the intestine and intestine-associated lymphoid organs.
It has recently been shown that the CD103 subset is active in
inducing Foxp3 Treg from Foxp3 T cells in the presence of
endogenous TGF, and that the DCs metabolize vitamin A to reti-
noic acid as an enhancing cofactor (40, 41). These reports found
that CD103 DCs from both mesenteric lymph node and lamina
propria could induce a small fraction of Foxp3 cells (2.5–9%)
from Foxp3 precursors.
In this study, we investigate the capacity of spleen DC subsets
to induce OVA-specific Foxp3 Treg. We find that CD8 spleen
DCs are selectively active and produce the required endogenous
TGF-, whereas CD8 spleen DCs require exogenous TGF- but
then become more proficient than CD8 DCs at inducing Treg.
We will also show that targeted in vivo Ag delivery to CD8
CD205 DCs but not CD8DCIR2 DCs likewise preferentially
induces Foxp3 Treg, even though CD8DCIR2 DCs more ef-
ficiently form peptide-MHC II complexes (35) and better expand
preformed natural Treg in vivo. These results indicate that the
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endogenous differentiation of Treg is controlled by select subsets




Specific pathogen free, 6- to 8-wk, female, C57BL/6 (B6) and BALB/c
mice were purchased from Taconic. DO11.10 RAG/ mice were obtained
through Taconic and the National Institute of Allergy and Infectious Dis-
eases (National Institutes of Health) Exchange Program (42), whereas
DO11.10 RAG/ mice were provided by Dr. P. Marrack (National Jewish
Medical and Research Center, Denver, CO). We received generous gifts of
OT-II mice from Dr. F. Carbone (University of Melbourne, Melbourne,
Australia), FIR (Foxp3-internal ribosomal entry site-linked monomeric red
fluorescent protein (RFP)) knockin mice from Dr. R. Flavell (Yale Uni-
versity, New Haven, CT) (43), and BALB/c Thy1.1 mice from Drs. M.
Lafaille and J. Lafaille (New York University, New York, NY). All mice
were used according to guidelines of the Institutional Animal Care and Use
Committee of The Rockefeller University (New York, NY).
Abs and reagents
PE-, FITC-, PerCP-Cy5.5-, or allophycocyanin-conjugated anti-CD25
(clone 7D4), CD25 (clone PC61), CD4 (clone H129.19), CD8, DX5, B220,
CD3, CD11c, streptavidin (SA) PE, SA-PE-Cy7, purified anti-CD16/CD32
(clone 2.4G2), anti-IL-10, and isotype rat Abs were from BD Pharmingen.
Anti-CD11c, FITC, streptavidin, PE, DX5, CD19, and CD90.2 microbeads
were from Miltenyi Biotec. Anti-DEC-205 (clone NLDC-145) and anti-
DCIR2 (clone 33D1) were purified and labeled with biotin or Alexa Fluor
6.418
76
















(µg/ml) 0.03 0.1 0.03 0.1
93
69



















































































FIGURE 1. CD8 splenic DCs
(SpDC) differentiate Foxp3 CD25
CD4 Treg from Foxp3 CD25
CD4 T cells in the absence of ex-
ogenous TGF- in vitro. A, Freshly
isolated Foxp3CD25CD4 T
cells from DO11.10 RAG/ mice
(2  104) were cultured with the in-
dicated doses of peptide and CD8
or CD8 DCs (2  104) in the ab-
sence or presence of TGF- (2 ng/
ml). After 5 days of culture, cells
were analyzed by FACS. Represen-
tative gates of CD4 CD11c cells
are shown on the left. B, As in A,
but the number of Foxp3 cells, the
percentage of Foxp3 T cells/CD4
T cells, and the number of CD4 T
cells per culture in the presence or
absence of TGF- are shown. The
number of Foxp3 cells at 0 g/ml
peptide was 102. A summary of
five to seven separate experiments
is shown; p values were provided by
Student’s t test.
















647 at the Monoclonal Antibody Core Facility of Memorial Sloan-Ketter-
ing Cancer Center (New York, NY) and The Rockefeller University.
CFSE, LIVE/DEAD fixable aqua cell stain, TOPRO-3, and streptavidin
Pacific blue was from Molecular Probes. Anti-mouse Foxp3 (clone FJK-
16s) staining kit and anti-CD4-Alexa Fluor 700 were from eBioscience.
Human TGF-1, anti-mouse TGF- mAb (clone 1D11), and isotype con-
trol were from R&D Systems. Human IL-2 was from Chiron. Anti-KJ1.26
mAb to the clonotypic receptor on OVA-specific DO11.10 TCR transgenic
T cells was from Caltag/Invitrogen. Polyinosinic-polycytidylic acid
(poly(I:C)) was from InVivoGen.
T cells and DCs
CD4 T cells were first negatively separated by MACS beads from lymph
nodes and spleen cell suspensions (90%) (Miltenyi Biotech) and further
purified by flow cytometry (99%). Spleen CD11c DCs were selected
with anti-CD11c beads and further purified by flow cytometry into CD8
or CD8 CD11cB220CD3DX5 DCs (95%). The DCs (2  104)
were irradiated (15 Gy) before coculture with T cells (2  104). The pu-
rified T cells and APCs were cultured in 96-well plates (Corning Costar)
with or without exogenous TGF- (2 ng/ml) in the presence of OVA pep-
tide (323–336). Live cell numbers per culture were calculated from the
yields from flow cytometry.
Flow cytometry
Cultured cells were first stained with anti-CD4, CD25, CD11c, and LIVE/
DEAD aqua stain with or without the other Abs and, after fixation, intra-
cellular Foxp3 was stained. BDLSRII, FACSort, FACSAria, or FACSDiva
flow cytometers were used (BD Biosciences). To assess cell numbers, all
Isotype AbAnti-TGF-β Ab
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FIGURE 2. CD8 DCs differentiate Foxp3CD25CD4 Treg using endogenous TGF-. A, Freshly isolated Foxp3CD25CD4 T cells from
DO11.10 RAG/ mice (2  104) were cultured with 0.03 g/ml peptide and CD8 DCs (2  104) in the presence of anti-TGF- mAb or isotype-matched
control mAb (10 g/ml). After 5 days of culture, cells were analyzed with FACS by gating on CD4 CD11c T cells. B, As in A, but the number of Foxp3
cells, the percentage of Foxp3 T cells/CD4 T cells, and the number of CD4 T cells per culture are shown. A summary of three separate experiments
is depicted; p values were provided by Student’s t test. C, As in A, but cells were cultured in the presence of anti-IL-10 mAb or isotype control mAb
(10 g/ml). After 5 days of culture, cells were analyzed with FACS by gating on CD4CD11c T cells. D, As in C, but the number of Foxp3 cells, the
percentage of Foxp3 T cells/CD4 T cells, and the number of CD4 T cells per culture are shown. These data are representative of three experiments.
SpDC, Splenic DCs.
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FIGURE 3. CD8 DCs produce TGF-. A, Total RNA was isolated from splenic CD8DEC-205 or CD8 DCIR2 DCs (SpDC). Affymetrix gene
array analysis showing relative levels of mRNAs associated with the TGF- and TGF- receptor signaling pathways expressed by CD8DCIR2 (left)
and CD8DEC-205 DCs (right) purified from B6 mice. Each lane consists of three independent microarrays of mRNAs from different cell sorts. B, CD8
or CD8 DCs from naive BALB/c mice or BALB/c mice that had been injected with poly(I:C) (PolyIC) 12 h before were cultured for 15–40 h in serum-free
medium, and the concentrations of TGF- in the supernatants were measured by ELISA. The concentration of TGF- in the serum-free medium was 0.
A summary of five separate experiments is shown; p value was provided by Student’s t test. C, CD8 or CD8 DCs from naive BALB/c mice or BALB/c
mice that had been injected with poly(I:C) 12 h before were purified by flow cytometry. Presort (top) and postsort (middle) plots are shown as gated on
CD11c cells. The purified cells were further stained with CD86 (black line) and isotype control Abs (shaded gray line) (bottom). D, The purified CD8
or CD8 DCs (2  104) from naive or poly(I:C) injected mice as in C were cultured with freshly isolated Foxp3CD25CD4 T cells from DO11.10
RAG/ mice (2  104) in the presence of 0.03 g/ml peptide. After 5 days of culture, cells were analyzed with FACS by gating on CD4CD11c T
cells. E, As in D, but the frequency of Foxp3 T cells/CD4 T cells per culture is also shown. These data are representative of three independent
experiments with each experiment done in triplicate. p value was provided by Student’s t test.
















cells were acquired from each culture and analyzed with FlowJo software
(Tree Star).
ELISA for TGF-
Spleen CD8 or CD8 DCs were purified by flow cytometry from naive
BALB/c mice or BALB/c mice that had been injected with 50 g poly(I:C)
12 h before. The purified DCs were cultured in serum-free Nutridoma
medium (Invitrogen) for 15–40 h. The concentrations of TGF- in the
supernatants were measured by TGF- ELISA kit (R&D Systems). Fol-
lowing the manufacturer’s instructions, we measured the TGF- with or
without activation of the latent form of TGF-.
Adoptive transfer of DO11.10 RAG/ CD4 T cells or
natural Treg
CFSE-labeled OVA-specific CD4 T cells from DO11 RAG/ mice (2 
106) were adoptively transferred into BALB/c Thy1.1 mice. The recipi-
ents were stimulated with indicated doses of chimeric anti-DEC-205 mAb
with OVA (DEC-OVA), chimeric anti-DCIR2 mAb (33D1) fused with
OVA (33D1-OVA), or chimeric isotype-matched mAb (Iso) fused with
OVA (Iso-OVA) i.p. 1 day later. After 10–14 days, a mixture of spleen and
lymph node cells was analyzed with FACS gating on the donor Thy1.2
cells. For natural Treg, CD25CD4 T cells from Thy1.2 DO11.10 trans-
genic mice were purified by flow cytometry and expanded with DCs, pep-
tide, and IL-2 for 1 wk (25). The expanded Treg or freshly isolated Treg
cells were CFSE labeled and adoptively transferred into BALB/c Thy1.1
recipients 1 day before injection with DEC-OVA or 33D1-OVA. After 3
and 14 days, mixtures of spleen and lymph nodes were evaluated with
FACS to monitor cell division by CFSE dilution and to enumerate Thy1.2
cells.
Production of chimeric mAbs
Chimeric mAbs (DEC-OVA, 33D1-OVA, and Iso-OVA) were produced
by transient transfection as described (21, 35). All mAbs were tested for
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CD8+ CD8– + TGF-β
Cultured with DC
FIGURE 4. Suppressive function of Foxp3CD25
CD4 Treg induced by CD8 or CD8 DCs. A, Foxp3
CD25CD4 T cells (2  104) from FIR-OTII mice were
cultured with spleen CD8 DCs (2  104) in the presence
of peptide (0.03–0.1 g/ml) without TGF-. After 5–6
days, the induced Foxp3CD25CD4 Treg and Foxp3
CD25CD4 T cells were purified by flow cytometry.
Similarly, Foxp3CD25CD4 T cells from FIR-OTII
mice were also cultured with spleen CD8 DCs in the
presence of peptide (0.03–0.1 g/ml) with TGF- (2 ng/
ml), and the induced Foxp3CD25CD4 Treg cells
were purified by flow cytometry. The insets in the presort
boxes indicate the gate for sorting. The purity of sorted
cells is also shown (postsort). B, For the suppression assay,
CD25CD4 responder T cells (1  104) from B6 mice
were CFSE-labeled and stimulated with spleen APCs (5 
104) and anti-CD3 mAb. To these, the suppressors (1 
104) as above were added. After 3 days, CFSE-dilution
was analyzed by flow cytometry. Dead cells were gated
out by TOPRO-3 iodide. These data are representative of
three independent experiments. C, As in B, but the number
of live CFSE CD25CD4 responder cells per culture
was shown. The indicated suppressors were added in the
culture at the indicated ratio. These data are representative
of two independent experiments.
















LPS contamination (Fisher-Cambrex) and decontaminated when necessary
(Pierce).
Gene array
We further investigated our previous gene array data (Gene Expression
Omnibus series accession no. GSE6259) (35). Briefly, CD11c DCs
were enriched from spleens of B6 mice by depletion of lymphocytes
with Abs to DX5, CD19, and CD90.2 on MACS beads (Miltenyi Bio-
tech). Cells were stained with DEC-205-biotin, then with CD11c-PE,
33D1 (anti-DCIR2)-Alexa Fluor 647, and SA-PE-Cy7 and purified by
cell sorting into CD11chighDCIR2highCD8 and CD11chighDEC-
205highCD8 on a FACSVantage. All cell samples were purified to
99% homogeneity. Total RNA was prepared using Qiagen RNeasy
Mini kit (Qiagen). DNA microarray analysis of gene expression was
performed at the gene array facility at Memorial Sloan-Kettering Can-
cer Center, Genomics Core Laboratory, New York). Fluorescent images
of hybridized microarrays (MOE 430 2.0 array; Affymetrix) were obtained
using an Affymetrix GeneChip Scanner. Microarray data was analyzed
using Affymetrix GeneSpring version 7.0 software. All samples were re-
peated at least three times with individually sorted cells and averaged.
Results
Peripheral differentiation of Foxp3 Treg in vitro is influenced
by the DC subset
Recently, it has been shown that DCs from mesenteric lymph
nodes induce some Foxp3 Treg cells using endogenous TGF-
(9). Given the specialized role of the CD103 DC subset from the
intestinal environment (40, 41), we hypothesized that a subset of
DCs in systemic lymphoid tissue might also have a role in induc-
ing Foxp3 Treg in the periphery. We therefore evaluated two
major CD8 and CD8 DC subsets from spleen, purifying these
on the FACS and adding the DCs to Foxp3CD25 CD4 T cells
from OVA-specific, DO11.10 RAG/ mice in the absence of
exogenous TGF-. After 5 days of culture, we observed that CD8
DCs, but not CD8 DCs, differentiated some Foxp3 Treg at two
doses of OVA peptide (Fig. 1, A and B, top). In contrast, after
addition of TGF- into the culture, CD8 DCs were more potent
inducers if the total numbers of newly formed Foxp3 Treg were
measured (Fig. 1, A and B, bottom). In the absence of Ag (Fig. 1B)
or the presence of a nonspecific MHC II binding peptide from
influenza virus hemagglutinin (data not shown), both CD8 DCs
and CD8 DCs did not induce Foxp3. These results indicate that
the minor subset of spleen CD8 DCs is able to differentiate
Foxp3 Treg in an Ag-dependent manner.
CD8 DCs use endogenous TGF- to differentiate Foxp3
Treg in vitro
The differentiation of Foxp3 Treg from Foxp3 cells occurs by
stimulation with TGF- (2–5, 9). To investigate whether endoge-
nous TGF- allows CD8 DCs to differentiate Foxp3 Treg, we
performed blocking experiments with neutralizing anti-TGF- and
control mAb (Fig. 2A). Anti-TGF- blocked the induction of
Foxp3 Treg by CD8 DCs, as measured by the percentage (Fig.
2A) and also the total numbers of induced Foxp3 Treg cells in the
culture (Fig. 2B). In addition to TGF-, we investigated the role of
IL-10, as IL-10 from pulmonary DCs helps to induce IL-10-pro-
ducing Tr1-type Treg (44). However, the induction of Foxp3
Treg by spleen CD8 DCs was not blocked by the presence of
neutralizing anti-IL-10 mAb in the culture (Fig. 2, C and D).
Therefore, it is unlikely that IL-10 has a role in the observed in-
duction of Foxp3 Treg by CD8 spleen DCs.
To verify that TGF- was being produced by DCs in the DC-T
cell cultures, and in particular by CD8CD205 DCs, we did mi-
croarray analyses on RNA from CD8CD205CD11c and
CD8DCIR2CD11c subsets. We found that CD8CD205
DCs selectively expressed TGF- and the TGF- binding protein
(Ltbp2) (Fig. 3A), which is important for the efficient secretion and
appropriate localization of latent TGF- (45). In contrast, CD8
DCIR2 DCs express TGF- receptor 1 and some members of the
SMAD family of transcription factors (Fig. 3A) that are activated
by TGF- receptors through phosphorylation (46). These results
imply that CD8 DCs can use endogenous TGF- to induce Treg
from Foxp3 precursors, whereas CD8 DCs are ready to respond
to TGF- that is provided from other types of cells.
To confirm the production of TGF- at the protein level, we
cultured CD8 or CD8 spleen DC subsets and measured TGF-
in the supernatants by ELISA (Fig. 3B). We compared TGF-
concentrations with or without activation of the latent form of
TGF-. Without activation, TGF- was not detected (data not
shown). With activation, we observed a significant amount of
TGF- in the supernatants, with CD8 spleen DCs producing
higher amounts of TGF- than CD8 spleen DCs (Fig. 3B). To
evaluate whether DC maturation affects the production of TGF-
by CD8 or CD8 DCs, we chose one maturation stimulus,
poly(I:C), because it acts as an effective adjuvant for DC-targeted
vaccine (47). When BALB/c mice were injected i.p. with 50 g of
poly(I:C) 12 h earlier, CD8 and CD8 DCs showed evidence
of maturation with higher CD86, CD40, and class II expression
(Fig. 3C and data not shown). When the purified DCs were cul-
tured, we found that the supernatants from the mature CD8 DCs
from poly(I:C)-injected mice contained less TGF- compared with
the immature CD8 DCs from naive mice (Fig. 3B). The mature
CD8 DCs from poly(I:C)-injected mice produced the same
amounts of TGF- as immature CD8 DCs (Fig. 3B). To evaluate
whether the reduction of TGF- production by mature DCs affects
the induction of Foxp3, CD8 DCs from poly(I:C)-injected mice
or noninjected naive mice were cultured with DO11.10 RAG/
CD4 T cells. The frequency of the induced Foxp3 Treg by the
mature CD8 DCs was much less than that by the immature CD8
DCs (Fig. 3, D and E). This indicates that spleen CD8 DCs in the
steady state produce a higher amount of a latent form of TGF-





















FIGURE 5. Treg proliferate during differentiation by DC subsets.
Foxp3 CD25CD4 T cells from DO11.10 RAG/ mice (2  104)
were CFSE labeled and cultured with CD8 DCs (2  104) without TGF-
(2 ng/ml) or CD8 DCs (2  104) with TGF- in the presence or absence
of OVA peptide (0.03 g/ml). At day 5, cells were stained with anti-Foxp3
mAb. Foxp3 expression and CFSE dilution are shown gated on live
CD11c CD4 T cells. This data are representative of three independent
experiments. SpDC, Splenic DCs.
















that is essential for induction of Foxp3 Treg than spleen CD8
DCs, and that one TLR ligand causes CD8 DCs to reduce TGF-
production.
Suppressive function of DC-induced Foxp3 Treg in vitro
To determine whether CD8 and CD8 DCs induce Foxp3 Treg
with suppressive function, we used FIR knockin mice that had
been crossed to OVA transgenic OT II B6 mice (FIR-OTII) (43) so
that we could then purify induced FIR, i.e., Foxp3 cells, to test
for suppression in an in vitro assay. Foxp3CD25CD4 T cells
from FIR-OTII mice were purified by flow cytometry and cultured
with CD8 DCs without TGF- or CD8 DCs with TGF-. After
5 days of culture, RFPCD25 and RFPCD25CD4 T cells
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FIGURE 6. DC targeting of OVA via DEC-205 leads to the development of Foxp3CD25CD4 T cells in vivo. A, Thy1.2 DO11.10 RAG/ mice lack
Foxp3CD25CD4 T cells as shown in the plots. The Foxp3CD25CD4 T cells were CFSE- labeled (2  106) and injected i.v. into Thy1.1 BALB/c mice.
The recipients were stimulated with indicated doses of DEC-OVA or 33D1-OVA i.p. 1 day later. After 3 or 10–14 days, spleen and lymph node Thy1.2 cells
were analyzed by FACS. B, As in A, but the frequencies of donor Thy1.2 DO11.10 RAG/ CD4 T cells within gates at day 3 are shown in the top row. Foxp3,
isotype control staining, and CFSE dilution gated on Thy1.2 transferred DO11.10 RAG/ CD4 T cells are shown in the middle and bottom rows. These data
are representative of two independent experiments. C, As in A, but the frequencies of donor Thy1.2 DO11.10 RAG/ CD4 T cells within gates at day 13 are
shown in the top row. Foxp3, isotype control staining and CFSE dilution gated on the Thy1.2 transferred DO11.10 RAG/ CD4 T cells are shown in the middle
and bottom rows. D, As in A, but recipient mice were stimulated with PBS, 3 g of DEC-OVA, or Iso-OVA i.p. 1 day later. After 13 days, a mixture of spleen
and lymph nodes was analyzed by FACS. Foxp3 (left), isotype control staining (right), and CFSE dilution gated on the Thy1.2 transferred DO11.10 RAG/
CD4 T cells are shown. Data are representative of three independent experiments. E, Cell recoveries of Foxp3Thy1.2 T cells from transferred DO11.10
RAG/ CD4 T cells at days 10–14 are shown as percentages per Thy1.2 T cells (left) and absolute numbers from each mouse (right). A summary of five
separate experiments where each data point is a separate experiment is shown; p value is from Student’s t test.
















vitro suppression assay comprised of CFSE-labeled CD25CD4
responder T cells stimulated with spleen APCs and anti-CD3 mAb
(Fig. 4, B and C). The proliferation of CD25CD4 T cells, as
indicated by CFSE dilution as well as by live responder cell
counts, was suppressed by the RFP CD25CD4 T cells induced
by CD8 DCs (Fig. 4, B and C). In contrast, the response of the
CFSE-labeled CD25CD4 cells was not inhibited by the addition
of RFP CD25CD4 T cells from the same culture (Fig. 4, B and
C). Similarly, the proliferation of CD25CD4 T cells was sup-
pressed by the RFP CD25CD4 T cells induced by spleen
CD8 DCs with TGF- (Fig. 4, B and C). Therefore, the Treg cells
induced by spleen DC subsets have suppressive function.
Proliferation of differentiating Treg upon stimulation with
spleen DC subsets
To investigate whether cell proliferation took place during the induc-
tion of Treg, CD4 T cells were isolated from DO11.10 RAG/
mice, CFSE labeled, and cultured with spleen CD8 DCs without
exogenous TGF- or CD8 DCs with exogenous TGF-. In both
instances, the newly formed Foxp3 Treg cells were almost entirely
derived from T cells that had undergone two to five cycles of cell
division (Fig. 5, see arrows). This result indicates that proliferating
cells are induced to express Foxp3 upon Ag stimulation with DCs.
OVA delivery to the CD8CD205 DC subset in vivo
selectively differentiates Foxp3 Treg
Ag delivery via DEC-205 mAb can induce Foxp3 Treg from
Foxp3 T cells (48), but it is not known whether Ag delivery to the
other DC subset via 33D1 mAb can also induce Foxp3. To com-
pare the induction of Treg by the two major DC subsets in vivo, we
adoptively transferred Foxp3CD25CD4 T cells from Thy1.2
DO11.10 RAG/ transgenic mice into Thy1.1 BALB/c mice
and stimulated them with OVA delivered by mAbs to DEC-205
(DEC-OVA) or DCIR2 (33D1-OVA) (35). The cells from
DO11.10 RAG/ transgenic mice were also CFSE-labeled before
transfer to follow cell proliferation in response to DEC-OVA or
33D1-OVA (Fig. 6A). Three days later, 33D1-OVA induced more
































































FIGURE 7. DC targeting of OVA
via 33D1 better sustains naturally oc-
curring Foxp3CD25CD4 T cells
in vivo. A, CD25CD4Foxp3 T
cells from Thy1.2 DO11.10 trans-
genic mice were cultured with mature
DCs, peptide, and IL-2. After 7 days,
the expanded Treg were 90% CD25
Foxp3. The expanded Treg
(0.51  106) cells were CFSE la-
beled and adoptively transferred into
Thy1.1 BALB/c mice. One day
later, the mice were i.p. injected with
3 g of 33D1-OVA or DEC-OVA Ab
or PBS. Spleen and lymph node cells
were mixed and analyzed by FACS at
day 3 or 14. B, Mixtures of spleen and
lymph node cells at day 3 or 10 after
injection of 33D1-OVA or DEC-
OVA Ab or PBS were stained with
anti-CD4 and anti-Thy1.2 (top).
Foxp3, isotype control staining, and
CFSE dilution gated on Thy1.2
transferred DO11.10 Treg cells are
shown in the middle and bottom rows.
C, As in A, but freshly isolated CFSE-
labeled Thy1.2 DO11.10 CD25
CD4 Treg cells were transferred into
Thy1.1 BALB/c mice. One day
later, the mice were i.p. injected with
3 g of 33D1-OVA or DEC-OVA
Ab, Iso-OVA, or PBS. Spleen and
lymph node cells were mixed and an-
alyzed by FACS at day 3. Data are
representative of two independent ex-
periments. D, As in A, but cell recov-
ery of Thy1.2 transferred DO11.10
Treg at day 10–14 is shown. A sum-
mary of five separate experiments is
shown; p value is from Student’s t
test.
















DEC-OVA (Fig. 6B). When expression of Foxp3 and CFSE dilu-
tion were assessed on these cells at day 3, proliferating cells ex-
pressed Foxp3 as indicated by the arrows, although 33D1-OVA
induced a greater proportion of proliferating Foxp3 cells (Fig.
6B). Ten to 14 days later, the numbers of recovered transferred
Thy1.2CD4 T cells showed a sizable reduction following the
3-g dose of the Ab-OVA proteins, suggesting T cell deletion as
a result of stimulation with either DEC-OVA or 33D1-OVA (Fig.
6C) as previously reported (21, 35, 49). When Foxp3 expression
and CFSE dilution were evaluated on the remaining Thy1.2 T
cells, Foxp3 was induced on undivided cells as well as on T cells
that had undergone cell division, but mainly in response to DEC-
OVA (3 g) rather than 33D1-OVA (Fig. 6C). Nevertheless,
33D1-OVA induced strong proliferation of CD4 T cells by the
cells that did not express Foxp3 (Fig. 6C). When a control isotype-
matched mAb fused with OVA (Iso-OVA) (35) was used,
DO11.10 T cells did not induce Foxp3 (Fig. 6D). The percentages
and numbers of the induced Foxp3 T cells were higher with 3 g
of DEC-OVA than with all tested doses of 33D1-OVA (Fig. 6E),
even though the CD8DCIR2 DC subset more rapidly produces
peptide-MHC II complexes (35). Thus, Ag delivery to CD8
CD205 DCs in vivo selectively induced more Foxp3 Treg cells
from Foxp3 precursors.
OVA delivery to the CD8DCIR2 DC subset in vivo better
expands natural Foxp3 Treg
It is not known how already existing natural Foxp3 Treg behave
after the targeting of Ags to DC-subsets in vivo. To address this
question, we compared the proliferation of Foxp3 Treg by DEC-
OVA and 33D1-OVA in vivo (35). Natural Foxp3 Treg from
Thy1.2 DO11.10 RAG/ OVA CD4 transgenic mice were pu-
rified by flow cytometry and expanded with DCs, peptide, and IL-2
for 1 wk (25). The expanded natural Treg (90% Foxp3) were
CFSE labeled and adoptively transferred into Thy1.1 BALB/c
recipients 1 day before injection with DEC-OVA or 33D1-OVA
(Fig. 7A). After 3 and 10–14 days, mixtures of spleen and lymph
node cells were evaluated for proliferation of Foxp3 Treg. We
used DC-expanded Foxp3 Treg for in vivo transfer because of the
larger number of cells after in vitro expansion. At day 3, more
transferred Thy1.2 DO11 Foxp3 Treg were observed after 3 g
of 33D1-OVA than 3 g of DEC-OVA (Fig. 7B). At day 10, the
Treg cells stimulated by both Abs were deleted compared with day
3; however, when Ag was delivered by 33D1, the transferred
Thy1.2 DO11 Treg cells were more numerous (Fig. 7B). When
the expression of Foxp3 and CFSE dilution were investigated, Ag
delivery by 33D1, in contrast to Ag delivery by DEC-205, induced
3 cell divisions and, importantly, the divided Treg maintained
high expression of Foxp3 (Fig. 7B). When Iso-OVA was used,
neither the DC-expanded Treg nor freshly isolated DO11.10 Treg
cells divided at day 3 as in PBS controls (freshly isolated Treg
cells are shown in Fig. 7C). Also, the absolute numbers of
Thy1.2Foxp3 Treg at day 10–14 were higher after stimulation
with 3 g of 33D1-OVA (Fig. 7D). Thus, Ag delivery to
CD8DCIR2 DCs, relative to CD8CD205 DCs in vivo, re-
sults in better stimulation of natural Foxp3 Treg.
Discussion
CD103 DCs in the intestinal environment are specialized to differ-
entiate Foxp3 Treg cells, and this contributes to the induction of oral
tolerance in the gut (40, 41). However, self-tolerance to tissue-specific
Ags also needs to be induced elsewhere in the body (18). We won-
dered whether DCs in systemic lymphoid organs could be involved in
inducing Treg in the periphery. We therefore investigated the capacity
of two major spleen DC subsets to differentiate Foxp3 Treg from
Foxp3 precursors. We found that CD8 CD205 DCs were selec-
tively active in vitro and in vivo. Therefore, CD8 CD205 DCs
from the spleen can differentiate Foxp3 Treg from Foxp3 precur-
sors in the periphery, as CD103 DCs can induce Foxp3 in the in-
testinal environment.
Mechanistic studies indicated that spleen CD8 CD205 DCs se-
lectively produced the requisite TGF- required for Treg differenti-
ation. Interestingly, CD8CD205 DCs also are specialized to take
up dying cells (50, 51). Presentation of allogeneic apoptotic cells by
CD8 DCs resulted in deletion of alloreactive T cells and induction
of Foxp3 Treg (52). Apoptotic cell death is associated with secretion
of anti-inflammatory cytokines such as TGF- (53). Therefore, it is
possible that CD8CD205 DCs in the steady state take up apoptotic
cells and that this triggers endogenous TGF- secretion.
CD103 DCs in the intestinal environment can differentiate
Foxp3 Treg with endogenous TGF- (40). TGF- is a cytokine
that is highly expressed in mucosal tissues (54, 55). CD103 DCs
in the intestine have retinal dehydrogenase to convert vitamin A or
retinal into retinoic acid, which is an essential cofactor for the
induction of Foxp3 Treg by TGF- (40, 41) and for the induction
of gut tropism for T cells and IgA-secreting B cells (56, 57). Lam-
ina propria macrophages also play a role in inducing Foxp3 Treg,
although TGF- needs to be added to the inductive cultures (58).
These findings suggest that the intestinal environment is special-
ized for inducing Foxp3 Treg for intestinal Ags.
When we examined the induction of Foxp3 Treg by DEC target-
ing in lymph nodes, we found that DEC-OVA induced Foxp3 in
lymph nodes (data not shown). CD8CD205 DCs from lymph
nodes also induced Foxp3 Treg in vitro (J. Idoyaga, S. Yamazaki,
and Ralph M. Steinman, unpublished data). However, CD8 DCs
from lymph nodes appear more complex than spleen DCs because
they can be divided into more subsets (12, 33). Other types of DCs
might participate in inducing Foxp3 Treg. More mature DCs in the
human thymus, following stimulation by thymic stromal lymphopoi-
etin, are responsible for generating natural Foxp3 Treg from
CD8CD4CD25 human thymocytes (59). Also, plasmacytoid
DCs are required for Ag-specific regulatory tolerance following donor
splenocyte transfusion plus anti-CD40 ligand mAb (60).
CD205 DCs are able to differentiate Foxp3 Treg in vivo fol-
lowing targeted delivery of Ag within mAb to DEC-205 (48, 61), but
it has been uncertain whether Foxp3 Treg cells are induced only by
Ag delivery to CD205 DCs. We found that Ag delivery to
CD8DCIR2 DCs in vivo is much less efficient for inducing
Foxp3 Treg from Foxp3 precursors. In vitro blocking assays, mi-
croarray, and ELISA results indicate that CD8CD205 DCs use
endogenous TGF-, in contrast to CD8DCIR2 DCs, to induce
Foxp3. Kretschmer et al. reported that Foxp3 Treg were more effi-
ciently induced with low doses of anti-DEC-205-hemagglutinin pep-
tide fusion mAb, which was a subimmunogenic condition (48). Ag
delivered by the 33D1 mAb to CD8 DCIR2 DCs in the steady state
are processed and transferred to the cell surface more efficiently as
MHC-class II peptide complexes (35). Therefore, it is also possible
that the amounts of MHC class II peptide complexes after Ag delivery
by anti-DEC-205 and 33D1 mAbs were different even though we
injected the same amounts of DEC-OVA and 33D1-OVA mAbs.
Our group previously reported that in vivo Ag delivery to CD205
DCs by DEC-205 mAb induced deletion of adoptively transferred
transgenic T cells (21, 35, 49). In these reports, we did not investigate
the induction of Foxp3 Treg in the remaining T cells, although other
groups have shown that Treg could be induced by DEC targeting (48,
61). Although Hawiger et al. (23) described that CD25 was not up-
regulated on the remaining T cells after DEC targeting, a higher dose
of anti-DEC-205 Ag and shorter observation times was used com-
pared with this study, and Foxp3 Abs were not used to monitor the
















response. In this study we confirmed that in vivo Ag delivery to CD8
CD205 DCs induce Foxp3 Treg on remaining T cells; however, it
has not been studied whether T cells stimulated by DEC targeting
actively induced apoptosis during the deletion process.
In contrast, Ag delivery to CD8 DCIR2 DCs stimulates nat-
ural Foxp3 Treg better than CD8 CD205 DCs in vivo. Natural
Treg proliferate in response to their selecting self-peptide in vivo
(62–65). CD8DCIR2 DCs excel in producing MHC class II-
peptide complexes compared with CD8CD205 DCs (35). This
might explain the better response by natural Foxp3CD25CD4
Treg to Ag delivery to CD8DCIR2 DCs. CD8 DCIR2 DCs
might have additional intrinsic differences to stimulate natural
Foxp3 Treg relative to CD8CD205 DCs beyond the prefer-
ential processing of the MHC class II pathway. For example, the
function of natural Foxp3 Treg is maintained by IL-2 (66–71),
and IL-2 is known to be produced from DCs stimulated with bac-
terial products (72). However, we did not see a difference in IL-2
expression by DC subsets in our gene array data (data not shown).
At the mRNA level, our gene array data showed that CD8
CD205 DCs expressed TGF- and TGF- binding protein, whereas
CD8 DCIR2 DCs expressed TGF- receptor and the downstream
transcription factors SMAD1 and SMAD4. This suggests that TGF-
from CD8CD205 DCs can act on Foxp3 precursors to induce
Foxp3, in contrast to CD8 DCIR2 DCs, which are ready to re-
spond to TGF-. DCs express v8 integrins, which activate latent
TGF-, and this process is important for induction and homeostasis of
Foxp3 Treg (73). TGF- could be provided by natural Foxp3 Treg
(74–76), and TGF- regulates the homeostasis and function of
Foxp3 Treg (75, 77, 78). T cells from TGF- receptor II dominant
negative mice did not induce Foxp3 after Ag delivery by DEC-205
mAb in vivo (48). Therefore, TGF- signaling on T cells seems to
play a role in inducing Foxp3 Treg in the periphery, but it is im-
portant to investigate whether TGF- signaling on DCs might addi-
tionally influence the induction of Treg.
We confirmed that spleen CD8 DCs produced higher amounts
of TGF- than spleen CD8 DCs by ELISA (Fig. 3B). DC mat-
uration is a complex subject because of the large number of dif-
ferent maturation stimuli and their different mechanisms of action.
However, we tested one of the stimuli, poly(I:C), and found that
maturing CD8 DCs in poly(I:C) reduced the production of
TGF-. Consistent with the idea that immature DCs are inducing
tolerance whereas mature DCs are actively inducing immunity
(18), we observed that the frequency of induced Foxp3 Treg was
reduced by poly(I:C)-matured CD8 DCs (Fig. 3, D and E). Fur-
ther studies are needed to understand how different maturation
stimuli affect the capacity of DC to induce Treg in vivo.
The factors that allow DCs to control the different pathways of
T cell differentiation need to be identified, because this will permit
a better understanding of DC function in vivo and in the design of
new immune-based treatments. Our findings indicate that endog-
enous production of TGF- in the context of a particular DC sub-
set in systemic lymphoid tissues, i.e., the CD8CD205 spleen
DC itself, permits the peripheral induction of Foxp3 Treg even in
the steady state. We propose that the delivery of Ag to CD8
CD205 DCs provides a means for the induction of therapeutic
Ag-specific Foxp3 Treg cells from Foxp3 T cells, as in auto-
immune diseases, allergy, or transplant rejection.
Acknowledgments
We thank Klara Velinzon and Tamara Shengelia for expert cell sorting, at
Memorial Sloan-Kettering Cancer Center Geneomics Core Laboratory for
performing gene arrays, Judy Adams for help with graphics, Lucio Verani
for help with references, Falk Nimmerjahn for reading the manuscript,
Maria Lafaille and Juan Lafaille for BALB/c Thy1.1 mice, and Richard
Flavell for FIR mice. DO11.10 RAG/ mice were obtained through the
National Institute of Allergy and Infectious Diseases Exchange Program.
Disclosures
M. C. Nussenzweig and R. M. Steinman have financial interests in Celldex,
which is developing anti-DEC-205 antibodies for human use. The other
authors have no conflicting financial interests.
References
1. Sakaguchi, S. 2004. Naturally arising CD4 regulatory T cells for immunologic
self-tolerance and negative control of immune responses. Annu. Rev. Immunol.
22: 531–562.
2. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and
S. M. Wahl. 2003. Conversion of peripheral CD4CD25 naive T cells to
CD4CD25 regulatory T cells by TGF- induction of transcription factor
Foxp3. J. Exp. Med. 198: 1875–1886.
3. Zheng, S. G., J. H. Wang, W. Stohl, K. S. Kim, J. D. Gray, and D. A. Horwitz.
2006. TGF- requires CTLA-4 early after T cell activation to induce FoxP3 and
generate adaptive CD4CD25 regulatory cells. J. Immunol. 176: 3321–3329.
4. Weber, S. E., J. Harbertson, E. Godebu, G. A. Mros, R. C. Padrick, B. D. Carson,
S. F. Ziegler, and L. M. Bradley. 2006. Adaptive islet-specific regulatory CD4 T
cells control autoimmune diabetes and mediate the disappearance of pathogenic
Th1 cells in vivo. J. Immunol. 176: 4730–4739.
5. Luo, X., K. V. Tarbell, H. Yang, K. Pothoven, S. L. Bailey, R. Ding,
R. M. Steinman, and M. Suthanthiran. 2007. Dendritic cells with TGF-1 dif-
ferentiate naive CD4CD25 T cells into islet-protective Foxp3 regulatory T
cells. Proc. Natl. Acad. Sci. USA 104: 2821–2826.
6. Davidson, T. S., R. J. Dipaolo, J. Andersson, and E. M. Shevach. 2007. IL-2 is
essential for TGF--mediated induction of Foxp3 T regulatory cells. J. Immu-
nol. 178: 4022–4026.
7. Bluestone, J. A. 2005. Regulatory T-cell therapy: is it ready for the clinic? Nat.
Rev. Immunol. 5: 343–349.
8. Shevach, E. M. 2006. From vanilla to 28 flavors: multiple varieties of T regula-
tory cells. Immunity 25: 195–201.
9. Yamazaki, S., A. J. Bonito, R. Spisek, M. Dhodapkar, K. Inaba, and
R. M. Steinman. 2007. Dendritic cells are specialized accessory cells along with
TGF- for the differentiation of Foxp3CD4 regulatory T cells from peripheral
Foxp3 precursors. Blood 110: 4293–4302.
10. Dipaolo, R. J., C. Brinster, T. S. Davidson, J. Andersson, D. Glass, and
E. M. Shevach. 2007. Autoantigen-specific TGF-induced Foxp3 regulatory T
cells prevent autoimmunity by inhibiting dendritic cells from activating autore-
active T cells. J. Immunol. 179: 4685–4693.
11. Reis e Sousa, C. 2006. Dendritic cells in a mature age. Nat. Rev. Immunol. 6:
476–483.
12. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine.
Nature 449: 419–426.
13. Villadangos, J. A., and P. Schnorrer. 2007. Intrinsic and cooperative antigen-
presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7:
543–555.
14. Figdor, C. G., Y. van Kooyk, and G. J. Adema. 2002. C-type lectin receptors on
dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2: 77–84.
15. Trombetta, E. S., and I. Mellman. 2005. Cell biology of antigen processing in
vitro and in vivo. Annu. Rev. Immunol. 23: 975–1028.
16. Lindquist, R. L., G. Shakhar, D. Dudziak, H. Wardemann, T. Eisenreich,
M. L. Dustin, and M. C. Nussenzweig. 2004. Visualizing dendritic cell networks
in vivo. Nat. Immunol. 5: 1243–1250.
17. Mempel, T. R., S. E. Henrickson, and U. H. Von Andrian. 2004. T-cell priming by
dendritic cells in lymph nodes occurs in three distinct phases. Nature 427: 154–159.
18. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic den-
dritic cells. Annu. Rev. Immunol. 21: 685–711.
19. Morelli, A. E., and A. W. Thomson. 2007. Tolerogenic dendritic cells and the
quest for transplant tolerance. Nat. Rev. Immunol. 7: 610–621.
20. Iwasaki, A. 2007. Mucosal dendritic cells. Annu. Rev. Immunol. 25: 381–418.
21. Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Ravetch,
R. M. Steinman, and M. C. Nussenzweig. 2001. Dendritic cells induce peripheral
T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:
769–780.
22. Probst, H. C., K. McCoy, T. Okazaki, T. Honjo, and M. van den Broek. 2005.
Resting dendritic cells induce peripheral CD8 T cell tolerance through PD-1 and
CTLA-4. Nat. Immunol. 6: 280–286.
23. Hawiger, D., R. F. Masilamani, E. Bettelli, V. K. Kuchroo, and M. C. Nussenzweig.
2004. Immunological unresponsiveness characterized by increased expression of
CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20: 695–705.
24. Dhodapkar, M. V., R. M. Steinman, J. Krasovsky, C. Münz, and N. Bhardwaj.
2001. Antigen specific inhibition of effector T cell function in humans after in-
jection of immature dendritic cells. J. Exp. Med. 193: 233–238.
25. Yamazaki, S., T. Iyoda, K. Tarbell, K. Olson, K. Velinzon, K. Inaba, and
R. M. Steinman. 2003. Direct expansion of functional CD25CD4 regulatory T
cells by antigen processing dendritic cells. J. Exp. Med. 198: 235–247.
26. Tarbell, K. V., S. Yamazaki, K. Olson, P. Toy, and R. M. Steinman. 2004.
CD25 CD4 T cells, expanded with dendritic cells presenting a single autoan-
tigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199: 1467–1477.
27. Fehervari, Z., and S. Sakaguchi. 2004. Control of Foxp3 CD25CD4 regu-
latory cell activation and function by dendritic cells. Int. Immunol. 16:
1769–1780.
















28. Levings, M. K., S. Gregori, E. Tresoldi, S. Cazzaniga, C. Bonini, and
M. G. Roncarolo. 2005. Differentiation of Tr1 cells by immature dendritic cells
requires IL-10 but not CD25CD4 Tr cells. Blood 105: 1162–1169.
29. Brinster, C., and E. M. Shevach. 2005. Bone marrow-derived dendritic cells
reverse the anergic state of CD4CD25 T cells without reversing their sup-
pressive function. J. Immunol. 175: 7332–7340.
30. Yamazaki, S., M. Patel, A. Harper, A. Bonito, H. Fukuyama, M. Pack,
K. V. Tarbell, M. Talmor, J. V. Ravetch, K. Inaba, and R. M. Steinman. 2006.
Effective expansion of alloantigen-specific Foxp3 CD25 regulatory T cells by
dendritic cells during the mixed leukocyte reaction. Proc. Natl. Acad. Sci. USA
103: 2758–2763.
31. Yamazaki, S., K. Inaba, K. V. Tarbell, and R. M. Steinman. 2006. Dendritic cells
expand antigen-specific Foxp3CD25CD4 regulatory T cells including sup-
pressors of alloreactivity. Immunol. Rev. 212: 314–329.
32. Crowley, M., K. Inaba, M. Witmer-Pack, and R. M. Steinman. 1989. The cell
surface of mouse dendritic cells: FACS analyses of dendritic cells from different
tissues including thymus. Cell. Immunol. 118: 108–125.
33. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat.
Rev. Immunol. 2: 151–161.
34. Nussenzweig, M. C., R. M. Steinman, M. D. Witmer, and B. Gutchinov. 1982. A
monoclonal antibody specific for mouse dendritic cells. Proc. Natl. Acad. Sci.
USA 79: 161–165.
35. Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. Buchholz, C. Trumpfheller,
S. Yamazaki, C. Cheong, K. Liu, H. W. Lee, C. G. Park, et al. 2007. Differential
antigen processing by dendritic cell subsets in vivo. Science 315: 107–111.
36. Pulendran, B., J. L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky, and
C. E. Maliszweski. 1999. Distinct dendritic cell subsets differentially regulate the
class of immune responses in vivo. Proc. Natl. Acad. Sci. USA 96: 1036–1041.
37. Maldonado-Lopez, R., T. De Smedt, P. Michel, J. Godfroid, B. Pajak,
C. Heirman, K. Thielemans, O. Leo, J. Urbain, and M. Moser. 1999. CD8a and
CD8 subclasses of dendritic cells direct the development of distinct T helper
cells in vivo. J. Exp. Med. 189: 587–592.
38. Maldonado-Lopez, R., C. Maliszewski, J. Urbain, and M. Moser. 2001. Cyto-
kines regulate the capacity of CD8 and CD8 dendritic cells to prime Th1/
Th2 cells in vivo. J. Immunol. 167: 4345–4350.
39. Soares, H., H. Waechter, N. Glaichenhaus, E. Mougneau, H. Yagita,
O. Mizenina, D. Dudziak, M. C. Nussenzweig, and R. M. Steinman. 2007. A
subset of dendritic cells induces CD4 T cells to produce IFN- by an IL-12-
independent but CD70-dependent mechanism in vivo. J. Exp. Med. 204:
1095–1106.
40. Coombes, J. L., K. R. Siddiqui, C. V. Arancibia-Carcamo, J. Hall, C. M. Sun,
Y. Belkaid, and F. Powrie. 2007. A functionally specialized population of mu-
cosal CD103 DCs induces Foxp3 regulatory T cells via a TGF-- and retinoic
acid-dependent mechanism. J. Exp. Med. 204: 1757–1764.
41. Sun, C. M., J. A. Hall, R. B. Blank, N. Bouladoux, M. Oukka, J. R. Mora, and
Y. Belkaid. 2007. Small intestine lamina propria dendritic cells promote de novo
generation of Foxp3 Treg cells via retinoic acid. J. Exp. Med. 204: 1775–1785.
42. Murphy, K. M., A. B. Heimberger, and D. Y. Loh. 1990. Induction by antigen of
intrathymic apoptosis of CD4CD8TCRlo thymocytes in vivo. Science 250:
1720–1723.
43. Wan, Y. Y., and R. A. Flavell. 2005. Identifying Foxp3-expressing suppressor T
cells with a bicistronic reporter. Proc. Natl. Acad. Sci. USA 102: 5126–5131.
44. Akbari, O., R. H. DeKruyff, and D. T. Umetsu. 2001. Pulmonary dendritic cells
producing IL-10 mediate tolerance induced by respiratory exposure to antigen.
Nat. Immunol. 2: 725–731.
45. Annes, J. P., J. S. Munger, and D. B. Rifkin. 2003. Making sense of latent TGF
activation. J. Cell Sci. 116: 217–224.
46. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006.
Transforming growth factor- regulation of immune responses. Annu. Rev. Im-
munol. 24: 99–146.
47. Trumpfheller, C., M. Caskey, G. Nchinda, M. P. Longhi, O. Mizenina, Y. Huang,
S. J. Schlesinger, M. Colonna, and R. M. Steinman. 2008. The microbial mimic
polyIC induces durable and protective CD4 T cell immunity together with a
dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. USA 105: 2574–2579.
48. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and
H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by
foreign antigen. Nat. Immunol. 6: 1219–1227.
49. Bonifaz, L., D. Bonnyay, K. Mahnke, M. Rivera, M. C. Nussenzweig, and
R. M. Steinman. 2002. Efficient targeting of protein antigen to the dendritic cell
receptor DEC-205 in the steady state leads to antigen presentation on major
histocompatibility complex class I products and peripheral CD8 T cell toler-
ance. J. Exp. Med. 196: 1627–1638.
50. Iyoda, T., S. Shimoyama, K. Liu, Y. Omatsu, Y. Akiyama, Y. Maeda,
K. Takahara, R. M. Steinman, and K. Inaba. 2002. The CD8 dendritic cell
subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med.
195: 1289–1302.
51. Liu, K., T. Iyoda, M. Saternus, K. Kimura, K. Inaba, and R. M. Steinman. 2002.
Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp.
Med. 196: 1091–1097.
52. Wang, Z., A. T. Larregina, W. J. Shufesky, M. J. Perone, A. Montecalvo,
A. F. Zahorchak, A. W. Thomson, and A. E. Morelli. 2006. Use of the inhibitory
effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and
regulatory T cells. Am. J. Transplant. 6: 1297–1311.
53. Huynh, M. L., V. A. Fadok, and P. M. Henson. 2002. Phosphatidylserine-depen-
dent ingestion of apoptotic cells promotes TGF- 1 secretion and the resolution
of inflammation. J. Clin. Invest. 109: 41–50.
54. Monteleone, G., F. Pallone, and T. T. MacDonald. 2004. Smad7 in TGF--me-
diated negative regulation of gut inflammation. Trends Immunol. 25: 513–517.
55. Barnard, J. A., G. J. Warwick, and L. I. Gold. 1993. Localization of transforming
growth factor  isoforms in the normal murine small intestine and colon. Gas-
troenterology 105: 67–73.
56. Iwata, M., A. Hirakiyama, Y. Eshima, H. Kagechika, C. Kato, and S. Y. Song.
2004. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21:
527–538.
57. Mora, J. R., M. Iwata, B. Eksteen, S. Y. Song, T. Junt, B. Senman, K. L. Otipoby,
A. Yokota, H. Takeuchi, P. Ricciardi-Castagnoli, et al. 2006. Generation of gut-
homing IgA-secreting B cells by intestinal dendritic cells. Science 314:
1157–1160.
58. Denning, T. L., Y. C. Wang, S. R. Patel, I. R. Williams, and B. Pulendran. 2007.
Lamina propria macrophages and dendritic cells differentially induce regulatory
and interleukin 17-producing T cell responses. Nat. Immunol. 8: 1086–1094.
59. Watanabe, N., Y. H. Wang, H. K. Lee, T. Ito, W. Cao, and Y. J. Liu. 2005.
Hassall’s corpuscles instruct dendritic cells to induce CD4CD25 regulatory T
cells in human thymus. Nature 436: 1181–1185.
60. Ochando, J. C., C. Homma, Y. Yang, A. Hidalgo, A. Garin, F. Tacke, V. Angeli,
Y. Li, P. Boros, Y. Ding, et al. 2006. Alloantigen-presenting plasmacytoid den-
dritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7: 652–662.
61. Mahnke, K., Y. Qian, J. Knop, and A. H. Enk. 2003. Induction of CD4/CD25
regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101:
4862–4869.
62. Cozzo, C., J. Larkin, III, and A. J. Caton. 2003. Cutting edge: self-peptides drive
the peripheral expansion of CD4CD25 regulatory T cells. J. Immunol. 171:
5678–5682.
63. Walker, L. S., A. Chodos, M. Eggena, H. Dooms, and A. K. Abbas. 2003. An-
tigen-dependent proliferation of CD4 CD25 regulatory T cells in vivo. J. Exp.
Med. 198: 249–258.
64. Klein, L., K. Khazaie, and H. von Boehmer. 2003. In vivo dynamics of antigen-
specific regulatory T cells not predicted from behavior in vitro. Proc. Natl. Acad.
Sci. USA 100: 8886–8891.
65. Apostolou, I., and H. Von Boehmer. 2004. In vivo instruction of suppressor
commitment in naive T cells. J. Exp. Med. 199: 1401–1408.
66. Furtado, G. C., M. A. de Lafaille, N. Kutchukhidze, and J. J. Lafaille. 2002.
Interleukin 2 signaling is required for CD4 regulatory T cell function. J. Exp.
Med. 196: 851–857.
67. Setoguchi, R., S. Hori, T. Takahashi, and S. Sakaguchi. 2005. Homeostatic main-
tenance of natural Foxp3 CD25 CD4 regulatory T cells by interleukin (IL)-2
and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201:
723–735.
68. Bayer, A. L., A. Yu, D. Adeegbe, and T. R. Malek. 2005. Essential role for
interleukin-2 for CD4CD25 T regulatory cell development during the neonatal
period. J. Exp. Med. 201: 769–777.
69. Malek, T., A. Yu, V. Vincek, P. Scibelli, and L. Kong. 2002. CD4 regulatory T
cells prevent lethal autoimmunity in IL-2R-deficient mice: implications for the
nonredundant function of IL-2. Immunity 17: 167–178.
70. D’Cruz, L. M., and L. Klein. 2005. Development and function of agonist-induced
CD25Foxp3 regulatory T cells in the absence of interleukin 2 signaling. Nat.
Immunol. 6: 1152–1159.
71. Fontenot, J. D., J. P. Rasmussen, M. A. Gavin, and A. Y. Rudensky. 2005. A
function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol.
6: 1142–1151.
72. Granucci, F., C. Vizzardelli, N. Pavelka, S. Feau, M. Persico, E. Virzi,
M. Rescigno, G. Moro, and P. Ricciardi-Castagnoli. 2001. Inducible IL-2 pro-
duction by dendritic cells revealed by global gene expression analysis. Nat. Im-
munol. 2: 882–888.
73. Travis, M. A., B. Reizis, A. C. Melton, E. Masteller, Q. Tang, J. M. Proctor,
Y. Wang, X. Bernstein, X. Huang, L. F. Reichardt, et al. 2007. Loss of integrin v8
on dendritic cells causes autoimmunity and colitis in mice. Nature 449: 361–365.
74. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell contact-dependent immu-
nosuppression by CD4 CD25 regulatory T cells is mediated by cell surface-
bound transforming growth factor . J. Exp. Med. 194: 629–644.
75. Green, E. A., L. Gorelik, C. M. McGregor, E. H. Tran, and R. A. Flavell. 2003.
CD4CD25 T regulatory cells control anti-islet CD8 T cells through TGF-
-TGF- receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. USA 100:
10878–10883.
76. Li, M. O., Y. Y. Wan, and R. A. Flavell. 2007. T cell-produced transforming
growth factor-1 controls T cell tolerance and regulates Th1- and Th17-cell
differentiation. Immunity 26: 579–591.
77. Huber, S., C. Schramm, H. A. Lehr, A. Mann, S. Schmitt, C. Becker,
M. Protschka, P. R. Galle, M. F. Neurath, and M. Blessing. 2004. Cutting edge:
TGF- signaling is required for the in vivo expansion and immunosuppressive
capacity of regulatory CD4CD25 T cells. J. Immunol. 173: 6526–6531.
78. Marie, J. C., J. J. Letterio, M. Gavin, and A. Y. Rudensky. 2005. TGF-1 main-
tains suppressor function and Foxp3 expression in CD4CD25 regulatory T
cells. J. Exp. Med. 201: 1061–1067.
6933The Journal of Immunology
 at R
ockefeller U
niversity L
ibrary on A
ugust 18, 2020
http://w
w
w
.jim
m
unol.org/
D
ow
nloaded from
 
